分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Visceral obesity-induced METTL27 regulation of the FABP5/PPARD/CPT1A axis in promoting colorectal cancer progression

Shengnan Gao, Qingxiao Fang, Zixuan Ru, Jun Xiang, Hongyu Liu, Na Lv, Kerou Li, Jingjing Li, Boyu Hou, Xu Yang, Hong Qiao

Journal:INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF:8.7

DOI:10.1016/j.ijbiomac.2026.150740

PMID:

Published:2026-02-05

research field:肿瘤学癌症代谢分子生物学代谢性疾病表观遗传学

Abstract

The incidence of obesity and colorectal cancer (CRC) is rising annually. Obesity, particularly visceral obesity, poses a serious health threat, yet the association of obesity with CRC progression, as well as the role of visceral obesity, remains debated. This study analyzed 394 CRC patients and revealed that both high body mass index (BMI) and visceral fat area (VFA) correlated with poor prognosis, with VFA being an independent risk factor. RNA sequencing and TCGA analysis showed that methyltransferase-like protein 27 (METTL27) was overexpressed in CRC tissues from patients with obesity (especially visceral obesity), and was associated with poor prognosis. Mechanistically, METTL27 activates the PPARD/CPT1A axis in an FABP5-dependent manner to promote CRC cell proliferation, migration, and invasion. Lipid metabolomics identified visceral obesity-specific fatty acids. In vitro, treatment with adipose tissue-conditioned medium (ACM) or visceral obesity-associated fatty acids induced lipid droplets accumulation and enhanced METTL27/FABP5/PPARD/CPT1A signaling, exacerbating CRC malignancy. This study is the first to elucidate METTL27's biological function, identifying it as a key upstream partner of FABP5, delineating its regulation of the FABP5/PPARD/CPT1A axis and its role in driving CRC progression in the context of visceral obesity, thereby providing new directions for therapeutic targets in CRC patients with visceral obesity.

本文使用的Yeasen产品

购物车
客服
转染试用